Advertisement

Neurourology pp 563-568 | Cite as

Disc Disease

  • Casey G. Kowalik
  • Joshua A. Cohn
  • Roger R. DmochowskiEmail author
Chapter

Abstract

Disc disease encompasses a variety of vertebral disorders including disc degeneration and herniation. Up to 80% of people will experience back pain over their lifetime and this can commonly be associated with degeneration of the intervertebral disc [1]. Degenerative disc disease is the clinical syndrome described by manifestations thought to be related to disc degeneration, characterized broadly by fissures, degeneration, and herniation. Disc herniation is the displacement of disc material, such as nucleus pulposus, beyond the disc edge [2]. Disc herniation occurs most commonly during the third and fourth decades of life with the most common levels of disc herniation being L4–L5 and L5–S1 [3]. Although lumbar disc herniation is the most common, cervical and thoracic discs can also herniate. The level and degree of disc herniation will affect patient symptoms.

References

  1. 1.
    National Institute of Neurologic Disorders and Stroke. 2015 [cited 21 Oct 2016]. http://www.ninds.nih.gov/disorders/backpain/detail_backpain.htm.
  2. 2.
    Fardon DF, Williams AL, Dohring EJ, Murtagh FR, Gabriel Rothman SL, Sze GK. Lumbar disc nomenclature: version 2.0 recommendations of the combined task forces of the North American Spine Society, the American Society of Spine Radiology and the American Society of Neuroradiology. Spine J. 2014;14:2525–45.CrossRefGoogle Scholar
  3. 3.
    Lauerman WC, Scherping SC, Wiesel SW. The spine. Essentials of orthopedic surgery, vol. 1. New York: Springer; 2011. p. 103–18.Google Scholar
  4. 4.
    Siracusa G, Sparacino A, Lentini VL. Neurogenic bladder and disc disease: a brief review. Curr Med Res Opin. 2013;29:1025–31.CrossRefGoogle Scholar
  5. 5.
    Goldman HB, Appell RA. Voiding dysfunction in women with lumbar disc prolapse. Int Urogynecol J. 1999;10:134–8.CrossRefGoogle Scholar
  6. 6.
    Tamburrelli FC, Genitiempo M, Bochicchio M, Donisi L, Ratto C. Cauda equina syndrome: evaluation of the clinical outcome. Eur Rev Med Pharmacol Sci. 2014;18:1098–105.PubMedGoogle Scholar
  7. 7.
    Fraser S, Roberts L, Murphy E. Cauda equina syndrome: a literature review of its definition and clinical presentation. Arch Phys Med Rehabil. 2009;90:1964–8.CrossRefGoogle Scholar
  8. 8.
    Ahn UM, Ahn NU, Buchowski JM, Garrett ES, Sieber AN, Kostuik JP. Cauda equina syndrome secondary to lumbar disc herniation. Spine. 2000;25:1515–22.CrossRefGoogle Scholar
  9. 9.
    Beculic H, Skomorac R, Jusic A, Alic F, Imamovic M, Mekic-Abazovic A, et al. Impact of timing on surgical outcome in patients with cauda equina syndrome caused by lumbar disc herniation. Med Glas. 2016;13:136–41.Google Scholar
  10. 10.
    Srikandarajah N, Boissaud-Cooke MA, Clark S, Wilby MJ. Does early surgical decompression in cauda equina syndrome improve bladder outcome? Spine. 2015;40:580–3.CrossRefGoogle Scholar
  11. 11.
    Ahad A, Elsayed M, Tohid H. The accuracy of clinical symptoms in detecting cauda equina syndrome in patients undergoing acute MRI of the spine. Neuroradiol J. 2015;28:438–42.CrossRefGoogle Scholar
  12. 12.
    Sylvester PA, McLoughlin J, Sibley GN, Dorman P, Kabala J, Ormerod I. Neuropathic urinary retention in the absence of neurological signs. Postgrad Med J. 1995;71:747–8.CrossRefGoogle Scholar
  13. 13.
    Yamanishi T, Yasuda K, Yuki T, Sakakibara R, Uchiyama T, Kamai T, et al. Urodynamic evaluation of surgical outcome in patients with urinary retention due to central lumbar disc prolapse. Neurourol Urodyn. 2003;22:670–5.CrossRefGoogle Scholar
  14. 14.
    Pannek J, Blok B, Castro-Diaz D, Del Popolo G, Kramer G, Radziszewski P, et al. Guidelines on neurogenic lower urinary tract dysfunction. 2013:1–64.Google Scholar
  15. 15.
    Bartolin Z, Savic I, Persec Z. Relationship between clinical data and urodynamic findings in patients with lumbar intervertebral disk protrusion. Urol Res. 2002;30:219–22.CrossRefGoogle Scholar
  16. 16.
    Dong D, Xu Z, Shi B, Chen J, Jiang X, Wang H. Clinical significance of urodynamic studies in neurogenic bladder dysfunction caused by intervertebral disk hernia. Neurourol Urodyn. 2006;25:446–50.CrossRefGoogle Scholar
  17. 17.
    Buttermann GR. Treatment of lumbar disc herniation: epidural steroid injection compared with discectomy. J Bone Joint Surg Am. 2004;86:670–9.CrossRefGoogle Scholar
  18. 18.
    Brooks ME, Moreno M, Sidi A, Braf ZF. Urologic complications after surgery on lumbosaral spine. Urology. 1985;26:202–4.CrossRefGoogle Scholar
  19. 19.
    Drake MJ, Apostolidis A, Cocci A, Emmanuel A, Gajewski JB, Harrison SCW, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence Committee of the Fifth International Consultation on Incontinence 2013. Neurourol Urodyn. 2016;35:657–65.CrossRefGoogle Scholar
  20. 20.
    Vasquez N, Knight SL, Susser J, Gall A, Ellaway PH, Craggs MD. Pelvic floor muscle training in spinal cord injury and its impact on neurogenic detrusor over-activity and incontinence. Spinal Cord. 2015;53:887–9. Nature Publishing Group.CrossRefGoogle Scholar
  21. 21.
    McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn. 2006;25:337–48.CrossRefGoogle Scholar
  22. 22.
    Lavelle RA, Coskun B, Bascu CD, Gliga LA, Christie AL, Lemack GE. Quality of life after suprapubic catheter placement in patients with neurogenic bladder conditions. Neurourol Urodyn. 2016;35:831–5.CrossRefGoogle Scholar
  23. 23.
    Kennelly MJ, DeVoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008;10:181–91.Google Scholar
  24. 24.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol. 2013;63:283–95.CrossRefGoogle Scholar
  25. 25.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20. Elsevier.CrossRefGoogle Scholar
  26. 26.
    Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2015;54:78–82. Nature Publishing Group.CrossRefGoogle Scholar
  27. 27.
    Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD, et al. Efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2016;11:e0159307–12.CrossRefGoogle Scholar
  28. 28.
    Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58:865–74. European Association of Urology.CrossRefGoogle Scholar
  29. 29.
    Engeler DS, Meyer D, Abt D, Müller S, Schmid HP. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol. 2015;15:105.CrossRefGoogle Scholar
  30. 30.
    Canbaz Kabay S, Kabay S, Mestan E, Cetiner M, Ayas S, Sevim M, et al. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2015;36:104–10.CrossRefGoogle Scholar
  31. 31.
    Martens FMJ, den PP H, Snoek GJ, Koldewijn EL, van Kerrebroeck PEVA, Heesakkers JPFA. Quality of life in complete spinal cord injury patients with a Brindley bladder stimulator compared to a matched control group. Neurourol Urodyn. 2011;30:551–5.CrossRefGoogle Scholar
  32. 32.
    Opisso E, Borau A, Rodríguez A, Hansen J, Rijkhoff NJM. Patient controlled versus automatic stimulation of pudendal nerve afferents to treat neurogenic detrusor overactivity. J Urol. 2008;180:1403–8.CrossRefGoogle Scholar
  33. 33.
    Farag FF, Martens FMJ, Rijkhoff NJM, Heesakkers JPFA. Dorsal genital nerve stimulation in patients with detrusor overactivity: a systematic review. Curr Urol Rep. 2012;13:385–8.CrossRefGoogle Scholar
  34. 34.
    Fandel TM, Trivedi A, Nicholas CR, Zhang H, Chen J, Martinez AF, et al. Transplanted human stem cell-derived interneuron precursors mitigate mouse bladder dysfunction and central neuropathic pain after spinal cord injury. Stem Cell. 2016;19:544–57. Elsevier.Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Casey G. Kowalik
    • 1
  • Joshua A. Cohn
    • 2
  • Roger R. Dmochowski
    • 1
    Email author
  1. 1.Department of Urologic SurgeryVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of UrologyEinstein Healthcare NetworkPhiladelphiaUSA

Personalised recommendations